DE04702967T1 - Behandlung von benigner prostatahyperplasie - Google Patents

Behandlung von benigner prostatahyperplasie Download PDF

Info

Publication number
DE04702967T1
DE04702967T1 DE04702967T DE04702967T DE04702967T1 DE 04702967 T1 DE04702967 T1 DE 04702967T1 DE 04702967 T DE04702967 T DE 04702967T DE 04702967 T DE04702967 T DE 04702967T DE 04702967 T1 DE04702967 T1 DE 04702967T1
Authority
DE
Germany
Prior art keywords
ionidamine
treatment
bph
patient
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE04702967T
Other languages
German (de)
English (en)
Inventor
George Portola Valley TIDMARSH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Templates Inc
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of DE04702967T1 publication Critical patent/DE04702967T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE04702967T 2003-01-17 2004-01-16 Behandlung von benigner prostatahyperplasie Pending DE04702967T1 (de)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US44111003P 2003-01-17 2003-01-17
US441110P 2003-01-17
US44234403P 2003-01-23 2003-01-23
US442344P 2003-01-23
US45866503P 2003-03-28 2003-03-28
US45866303P 2003-03-28 2003-03-28
US45884603P 2003-03-28 2003-03-28
US458663P 2003-03-28
US458846P 2003-03-28
US458665P 2003-03-28
US46001203P 2003-04-02 2003-04-02
US460012P 2003-04-02
US47290703P 2003-05-22 2003-05-22
US472907P 2003-05-22
US48826503P 2003-07-18 2003-07-18
US488265P 2003-07-18
US49616303P 2003-08-18 2003-08-18
US496163P 2003-08-18
PCT/US2004/001141 WO2004064735A2 (en) 2003-01-17 2004-01-16 Treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
DE04702967T1 true DE04702967T1 (de) 2006-06-22

Family

ID=32777423

Family Applications (1)

Application Number Title Priority Date Filing Date
DE04702967T Pending DE04702967T1 (de) 2003-01-17 2004-01-16 Behandlung von benigner prostatahyperplasie

Country Status (13)

Country Link
US (4) US6989400B2 (enExample)
EP (2) EP1610778A4 (enExample)
JP (2) JP2006518343A (enExample)
KR (2) KR20050098250A (enExample)
AU (2) AU2004206870A1 (enExample)
BR (1) BRPI0406796A (enExample)
CA (2) CA2513572A1 (enExample)
DE (1) DE04702967T1 (enExample)
ES (1) ES2254046T1 (enExample)
IL (1) IL169685A0 (enExample)
MX (2) MXPA05007571A (enExample)
NO (1) NO20053783L (enExample)
WO (2) WO2004064735A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US7524885B2 (en) * 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
WO2004064735A2 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia
BRPI0512161A (pt) 2004-06-17 2008-02-12 Wisconsin Alumni Res Found métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica
WO2006091790A1 (en) 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
WO2007101148A2 (en) * 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
WO2009014150A1 (ja) 2007-07-24 2009-01-29 Astellas Pharma Inc. ベンズイミダゾール誘導体
SI2181990T1 (sl) 2007-08-31 2012-10-30 Astellas Pharma Inc Piperidinski derivat
US8603123B2 (en) 2008-04-28 2013-12-10 Urotech, Inc. Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration
DK2331092T3 (da) 2008-08-21 2014-05-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
AU2010208062B2 (en) * 2009-01-29 2014-07-24 Kodiscovery, Llc Compositions and methods for the treatment of cancer
WO2013153821A1 (ja) * 2012-04-12 2013-10-17 Omura Satoshi Ｐｄｋ４阻害剤及びその利用
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
JP6552509B2 (ja) 2014-01-14 2019-07-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 選択的ａｔｐ阻害剤をカプセル化するシクロデキストリン組成物およびその使用
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
CN116438162A (zh) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
SK72996A3 (en) 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
FR2737721B1 (fr) * 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
ATE202551T1 (de) 1995-10-18 2001-07-15 Kanoldt Arzneimittel Gmbh Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
DE19621319A1 (de) 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
IT1289939B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用
EP1083896A4 (en) * 1998-05-11 2002-09-11 Endowment For Res In Human Bio USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6001865A (en) * 1999-05-04 1999-12-14 Angelini Pharmaceuticals Inc. 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents
WO2004064735A2 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia
SG151299A1 (en) * 2004-03-25 2009-04-30 Univ Michigan Gossypol co-crystals and the use thereof

Also Published As

Publication number Publication date
AU2004206870A1 (en) 2004-08-05
JP2006518343A (ja) 2006-08-10
US20050272796A1 (en) 2005-12-08
MXPA05007571A (es) 2005-11-17
WO2004064736A2 (en) 2004-08-05
AU2004206869A1 (en) 2004-08-05
US20050271723A1 (en) 2005-12-08
NO20053783D0 (no) 2005-08-09
US20040167196A1 (en) 2004-08-26
MXPA05007572A (es) 2005-11-17
KR20050098249A (ko) 2005-10-11
BRPI0406796A (pt) 2006-01-17
EP1592430A2 (en) 2005-11-09
EP1592430A4 (en) 2006-05-31
JP2006516571A (ja) 2006-07-06
US6989400B2 (en) 2006-01-24
IL169685A0 (en) 2007-07-04
US20050272795A1 (en) 2005-12-08
WO2004064735A3 (en) 2004-12-16
WO2004064736A3 (en) 2005-05-06
NO20053783L (no) 2005-09-27
CA2513572A1 (en) 2004-08-05
EP1610778A2 (en) 2006-01-04
EP1610778A4 (en) 2006-05-31
CA2513575A1 (en) 2004-08-05
KR20050098250A (ko) 2005-10-11
ES2254046T1 (es) 2006-06-16
WO2004064735A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
DE04702967T1 (de) Behandlung von benigner prostatahyperplasie
DE69431729T2 (de) Bromocryptin enthaltende mittel mit beschleunigter freisetzung
DE4344405C2 (de) Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE19705229C2 (de) Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE69417733T2 (de) Verfahren zur hemmung des knochenschwundes mit 3,4-diarylchroman
DE60003010T2 (de) Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata
DE06075704T1 (de) Vorbeugung und Behandlung von amyloidogener Krankheit
DE60213648T2 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
EP1319404A2 (de) Mittel zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP0023994B1 (de) Zahnmedizinische Wurzelfüllpaste
Gazi The finding of antiplaque features in Acacia Arabica type of chewing gum
EP2222292A2 (de) Neue verwendung von omega-3-fettsäure(n)
EP0037488B1 (de) Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen
EP0885005B1 (de) Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann
DE60112750T2 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
DE60306133T2 (de) Verbindung eines antithrombotischen mittels mit aspirin und dessen verwendung zur behandlung von atherothrombotischen erkrankungen
AT398372B (de) Verfahren zur prophylaxe der hypokalzämischen gebärlähmung und der atypischen gebärparese des rindes
DE69426317T2 (de) Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation
DE102021119031B4 (de) Behandlung von Polymyalgia Rheumatica
Van der Rhee et al. Treatment of psoriasis vulgaris with a low-dosage Ro 10-9359 (Tigason) orally combined with corticosteroids topically
Vuopala et al. Dimethyl Sulfoxide (DMSO) Ointment in the Treatment of Rheumatoid Arthritis: A Double Blind Study
DE2048926C2 (de) Antihypertensives Kombinationspräparat
DE3872571T2 (de) Mischung mit einem gehalt an einem zentralanalgetikum und forskolin als wirkstoffe.
DE69009538T2 (de) In der Therapeutik anwendbare Zusammensetzung mit aggregationshemmender Wirkung auf Blutplättchen.
DE69931696T2 (de) Arzneimittel zur Verminderung der Effekte während oder nach der Menopause und Verfahren zur Behandlung und Verwendung derselben